The phase III BEACON-CRC trial demonstrated that these BRAF-targeted combination therapies achieve longer progression-free survival (PFS) and higher overall survival (OS) than standard therapies, including CET and irinotecan [5]. The gene discussed is BRAF; the disease is colorectal carcinoma.